top of page
  • Writer's pictureSBIJI Innovation

Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopia

Orasis Advances Presbyopia Candidate to Phase 3 Clinical Trials

HERZLIYA, Israel, September 10, 2020 – Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the treatment of presbyopia symptoms, today announced the closing of a $30 million Series C financing. The financing was co-led by new investor Bluestem Capital and returning investor Visionary Ventures, with participation from other returning investors Sequoia Capital, SBI (Japan) Innovation Fund, Maverick Ventures Israel, LifeSci Venture Partners and additional investors. Tyler J. Stowater, partner and vice president of Bluestem Capital, will join the Orasis Board of Directors in conjunction with the financing.

8 views0 comments

Recent Posts

See All


bottom of page